All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @kmartfit on TikTok · 16s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @kmartfit's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Do not inject testosterone once a week because testosterone-sipping it has an eight-day half-life.
  2. 0:04And what this means is that four days into your injection, you feel phenomenal. But once that
  3. 0:08fifth day hits, your levels start to crash, causing you to feel more low testosterone symptoms.
  4. 0:13You need to inject twice a week, period.

@kmartfit's weekly testosterone shot advice, fact-checked

KMART

TikTok creator

522.7K viewsWatch on TikTok

Quick answer

Testosterone cypionate has a well-documented half-life of approximately 7 to 8 days, which produces measurable trough-to-peak fluctuations on weekly injection schedules. Splitting doses to twice weekly is a common clinical strategy to reduce these fluctuations, but individual response varies significantly based on SHBG, injection volume, and patient physiology. Injection frequency should be determined through lab-guided, provider-supervised protocol adjustment, not generalized social media guidance.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @kmartfit's weekly testosterone shot advice, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@kmartfit's weekly testosterone shot advice, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@kmartfit's weekly testosterone shot advice, fact-checked" from KMART. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Testosterone cypionate has a well-documented half-life of approximately 7 to 8 days, which produces measurable trough-to-peak fluctuations on weekly injection schedules.

The reason this review is not generic is the source wording and the canonical claim label "trt don t inject once a week trt trtgains trt101 trtfamily." In this clip, the useful excerpt is: "Do not inject testosterone once a week because testosterone-sipping it has an eight-day half-life." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Peak serum levels after injection typically occur within 24 to 72 hours, not day four, according to FDA prescribing data for Depo-Testosterone.
People who land here are usually comparing the Testosterone claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Testosterone cypionate has a well-documented half-life of approximately 7 to 8 days, which produces measurable trough-to-peak fluctuations on weekly injection schedules.

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Testosterone cypionate has a well-documented half-life of approximately 7 to 8 days, which produces measurable trough-to-peak fluctuations on weekly injection schedules. Splitting doses to twice weekly is a common clinical strategy to reduce these fluctuations, but individual response varies significantly based on SHBG, injection volume, and patient physiology. Injection frequency should be determined through lab-guided, provider-supervised protocol adjustment, not generalized social media guidance.
  • Testosterone cypionate's half-life is 7 to 8 days per Behre et al. (1999), meaning weekly injections do produce measurable level drops before the next dose.
  • Peak serum levels after injection typically occur within 24 to 72 hours, not day four, according to FDA prescribing data for Depo-Testosterone.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Testosterone cypionate's half-life is 7 to 8 days per Behre et al. (1999), meaning weekly injections do produce measurable level drops before the next dose.
  • Peak serum levels after injection typically occur within 24 to 72 hours, not day four, according to FDA prescribing data for Depo-Testosterone.
  • Twice-weekly injections reduce peak-to-trough variability and are a widely used clinical strategy, but they are not the only valid option for every patient.
  • Inter-individual variability in testosterone kinetics is significant, meaning symptom timing mid-cycle differs between patients based on SHBG, metabolism, and dose.
  • Ramasamy et al. (2021, Translational Andrology and Urology) found no single injection frequency is universally optimal, reinforcing the need for individualized protocols.
  • Patients experiencing cyclical low-T symptoms should bring trough lab values and a symptom log to their provider rather than adjusting injection schedules based on social media advice.
  • Injection frequency is a clinical decision that depends on lab monitoring, patient tolerance, hematocrit levels, and lifestyle factors, none of which a TikTok video can assess.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @kmartfit actually say?

@kmartfit's argument is simple: testosterone cypionate has an "eight-day half-life," so injecting once a week means your levels peak around day four and then "start to crash" by day five. The fix, according to them, is injecting "twice a week, period." No caveats, no nuance, just a blanket rule for everyone on TRT.

The advice isn't fringe. Split-dosing testosterone is genuinely common practice in clinical TRT circles, and the reasoning they gave tracks with basic pharmacokinetics. But the way they framed it, as an absolute rule with a specific crash timeline, deserves a closer look.

Does the science back this up?

Partially, yes. The half-life claim is roughly correct, and the logic about level fluctuations is real. But the specific "day four peak, day five crash" timeline is oversimplified and not supported by pharmacokinetic data as a universal experience.

Testosterone cypionate's half-life is typically cited between 7 and 8 days (Behre et al., 1999, Clinical Endocrinology). The peak serum concentration after a single injection generally occurs around 24 to 72 hours post-injection, not day four, according to FDA prescribing data for Depo-Testosterone. By day seven to eight, levels have dropped to roughly 50% of peak. So the broad arc of their argument holds: levels do fall meaningfully before the next weekly injection. But symptom timing varies considerably between individuals based on SHBG levels, metabolic rate, injection volume, and baseline testosterone. A study by Zitzmann et al. (2006, Journal of Clinical Endocrinology and Metabolism) found significant inter-individual variability in testosterone kinetics after injection, meaning "day five crash" is not a universal biological event.

What did they get wrong (or right)?

They got the core pharmacology directionally right. Weekly injections do produce more pronounced peaks and troughs than twice-weekly injections, and some patients genuinely do feel worse in the back half of their injection cycle. That's a documented clinical reality.

What they got wrong is the certainty. Saying "do not inject once a week" as an absolute ignores that some patients tolerate weekly injections well, particularly those with lower SHBG or who use smaller doses. There is also a legitimate case for less frequent injections in certain protocols. The claim that symptoms "start to crash" on a predictable day-five schedule treats every patient's endocrine system identically, which no endocrinologist would do. Research from Snyder et al. (2000, Annals of Internal Medicine) showed that symptom response to testosterone therapy varies widely based on individual physiology, comorbidities, and baseline hormone status. The "period" at the end of their sentence is doing a lot of work that the evidence doesn't fully support.

What should you actually know?

If you're on TRT and feeling worse in the second half of your weekly injection cycle, splitting your dose into two smaller twice-weekly injections is a reasonable thing to discuss with your prescriber. Many clinicians do prefer this approach for exactly the reasons @kmartfit described: more stable serum levels, fewer symptom fluctuations, and a smoother hormonal environment.

But injection frequency is a clinical decision, not a TikTok rule. Factors like your SHBG level, hematocrit, injection tolerance, and lifestyle all matter. Some patients on once-weekly protocols have stable, symptom-free results. Others do better on twice-weekly or even subcutaneous micro-dosing. A 2021 review by Ramasamy et al. (Translational Andrology and Urology) noted that no single injection protocol is universally optimal, and individualized dosing guided by lab monitoring remains the standard of care.

If you're experiencing cyclical low-T symptoms mid-week, bring your symptom log and trough lab values to your provider. That conversation is more useful than any TikTok video, including this one.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

KMART · TikTok creator

522.7K views on this video

Don't inject once a week #Trt #trtgains #trt101 #trtfamily #trttransformation #trtshots #trtshot #trtforlife #trtdays #trtcommunity #trtbeforeandafter #trtlife #trtgainz #trtformen #trtworld #trtn

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about testosterone cypionate's half-life?

Testosterone cypionate's half-life is 7 to 8 days per Behre et al. (1999), meaning weekly injections do produce measurable level drops before the next dose.

What does the video say about peak serum levels after injection typically occur within 24 to?

Peak serum levels after injection typically occur within 24 to 72 hours, not day four, according to FDA prescribing data for Depo-Testosterone.

What does the video say about twice-weekly injections reduce peak-to-trough variability?

Twice-weekly injections reduce peak-to-trough variability and are a widely used clinical strategy, but they are not the only valid option for every patient.

What does the video say about inter-individual variability in testosterone kinetics?

Inter-individual variability in testosterone kinetics is significant, meaning symptom timing mid-cycle differs between patients based on SHBG, metabolism, and dose.

What does the video say about ramasamy et al. (2021, translational andrology?

Ramasamy et al. (2021, Translational Andrology and Urology) found no single injection frequency is universally optimal, reinforcing the need for individualized protocols.

What does the video say about patients experiencing cyclical low-t symptoms should bring trough lab values?

Patients experiencing cyclical low-T symptoms should bring trough lab values and a symptom log to their provider rather than adjusting injection schedules based on social media advice.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Not medical advice. This video was made by KMART, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.